Sanofi invests in new biologics

Country

France

Sanofi SA stepped up its acquisition activities in late December 2021 with plans to buy a US company with an advanced biologics platform. Sanofi is to pay $1 billion upfront for San-Francisco-based Amunix Pharmaceuticals Inc whose lead product, AMX-818, is poised to enter clinical development in early 2022 for patients with HER2 breast cancer. Amunix is developing biologics that crosslink tumours and T cells in order to induce the destruction of cancer cells.